Literature DB >> 4789106

Plasma concentration of levodopa in patients with Parkinson's disease.

U K Rinne, V Sonninen, T Siirtola.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4789106     DOI: 10.1159/000114285

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  9 in total

1.  Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors:  G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

4.  "On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.

Authors:  T Eriksson; T Magnusson; A Carlsson; A Linde; A K Granérus
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

Review 5.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

6.  Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.

Authors:  U K Rinne; E Birket-Smith; E Dupont; E Hansen; M Hyyppä; R Marttila; B Mikkelsen; H Pakkenberg; J Presthus
Journal:  J Neurol       Date:  1975-12-02       Impact factor: 4.849

7.  Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?

Authors:  J R Hughes; S G Bowes; A L Leeman; C J O'Neill; A A Deshmukh; P W Nicholson; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

8.  Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.

Authors:  R Katzenschlager; A Evans; A Manson; P N Patsalos; N Ratnaraj; H Watt; L Timmermann; R Van der Giessen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

9.  Treatment of idiopathic Parkinson's disease with traditional chinese herbal medicine: a randomized placebo-controlled pilot clinical study.

Authors:  Wan Fung Kum; Siva Sundara Kumar Durairajan; Zhao Xiang Bian; Sui Cheung Man; Yuen Chi Lam; Li Xia Xie; Jia Hong Lu; Yan Wang; Xian Zhang Huang; Min Li
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-18       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.